Results 51 to 60 of about 552 (131)

EFFICACY AND SAFETY OF OLOKIZUMAB IN THE MANAGEMENT OF RHEUMATOID ARTHRITIS- A SYSTEMATIC REVIEW AND META-ANALYSIS

Journal of Ayub Medical College Abbottabad
Background: Olokizumab (OKZ) is a monoclonal antibody against the interleukin receptor-6 that has shown promise in recent phase II and III trials in patients of rheumatoid arthritis (RA). This meta-analysis aims to evaluate the efficacy and safety of Olokizumab in managing rheumatoid arthritis.
Saad, Khalid, Laiba, Imran, Muhammad, Uzair, Javeria, Tirmizi, Ayesha, Khan, Suman, Tashkil, Anas, Adil   +6 more
openaire   +2 more sources

Experience of using the interleukin-6 inhibitor olokizumab in patients with rheumatoid arthritis in real-life clinical practice (based on data from Tyumen Regional Rheumatology Center)

Современная ревматология
The Tyumen Regional Rheumatology Center has gained experience in the use of the interleukin-6 inhibitor olokizumab (OKZ) in the treatment of patients with rheumatoid arthritis (RA).Objective: to evaluate the efficacy and safety of OKZ therapy in patients
I. M. Patrikeeva, Yu. A. Lushpaeva, N. V. Knaub, E. A. Ustinova, O. A. Belikov, M. B. Dolgikh, T. Yu. Malysheva   +6 more
doaj   +1 more source

Results of a 24-week open-label, non-interventional study on the efficacy and safety of olokizumab therapy in patients with rheumatoid arthritis after switching from anti-B-cell therapy during the SARS-CoV-2 pandemic

Современная ревматология
In the context of the new coronavirus infection (NCI) COVID-19 pandemic, the rheumatological community is facing new challenges in the treatment of immune-inflammatory rheumatic diseases (IIRDs).
A. V. Fedorova, N. E. Banshchikova, A. E. Sizikov, A. A. Mullagaliev, E. A. Letyagina, A. A. Akimova, N. A. Ilyina, Yu. D. Kurochkina, Yu. B. Ubshaeva, V. O. Omelchenko, O. A. Chumasova, N. S. Shkaruba, M. A. Korolev   +12 more
doaj   +1 more source

Efficacy of tofacitinib, upadacitinib and olokizumab in rheumatoid arthritis in real clinical practice

Russian Medical Inquiry
Aim: to perform an indirect comparative analysis of changes over time in clinical and laboratory parameters of inflammatory activity of rheumatoid arthritis (RA) in patients who receive tofacitinib (TOFA), upadacitinib (UPA), and olokizumab (OKZ) in real clinical practice.
N.A. Lapkina, A.A. Baranov, E.A. Leont'eva, V.N. Amirdzhanova, A.A. Kolin'ko, G.M. Ashikhmin   +5 more
openaire   +1 more source

Quantitative Signal Detection for COVID-19 Medicinal Products Based on Retrospective Analysis of Spontaneous Reports from the Russian Pharmacovigilance Database

Безопасность и риск фармакотерапии
SCIENTIFIC RELEVANCE. The pandemic of novel coronavirus infection (COVID-19) led to a drastic increase in the use of medicinal products of various therapeutic groups and increased spontaneous reporting of adverse drug reactions (ADRs).
S. A. Mishinova, A. S. Kolbin, Yu. S. Polushin, E. V. Verbitskaya   +3 more
doaj   +1 more source

Interleukin-6 inhibition in the management of non-infectious uveitis and beyond

Journal of Ophthalmic Inflammation and Infection, 2019
Background Uveitis consists of a spectrum of inflammatory disorders characterized by ocular inflammation. The underlying pathophysiology consists of a complex interplay of various inflammatory pathways.
Samendra Karkhur, Murat Hasanreisoglu, Erin Vigil, Muhammad Sohail Halim, Muhammad Hassan, Carlos Plaza, Nam V. Nguyen, Rubbia Afridi, Anh T. Tran, Diana V. Do, Yasir J. Sepah, Quan Dong Nguyen   +11 more
doaj   +1 more source

Olokizumab effectively improved symptoms of rheumatoid arthritis in an open-label observational study

Clinical pharmacology and therapy
Clinical manifestations of rheumatoid arthritis (RA), that is, pain, fatigue, functional impairment, and central sensitization, are closely related to the hyperproduction of interleukin (IL)-6. Therefore, IL-6 inhibitors (iIL-6), such as olokizumab (OKZ), can improve both RA activity and main symptoms of the disease.
A.M. Lila, A. Egorova, A. Chudinov, T. Chernykh, E. Timoshenko, L. Solodovnikova, A. Sizikov, A. Rybin, A. Pavlova, N. Nikulenkova, M. Mokrousova, I. Melekhina, L. Masneva, I. Marusenko, N. Lapkina, E. Krukova, M.A. Korolev, D. Karateev, O. Ershova, O. Epifanova, S. Davidyan, Yu. Grabovetskaya, E.A. Bogdanova, O. Anoshenkova, A. Karateev   +24 more
openaire   +1 more source

Clinical indicators of the efficacy of therapy with olokizumab in patients with COVID-19 infection

Messenger of ANESTHESIOLOGY AND RESUSCITATION
Introduction. A new form of coronavirus δ (SARS-CoV-2) caused the development of the global COVID-19 pandemic in 2019–2022, which claimed more than 7 million lives. COVID-19 infection is accompanied by a rapid deterioration in the health of patients with the development of a generalized systemic inflammatory ...
S. R. Khobotnikova, D. N. Khobotnikov, A. Yu. Asinovskaya, O. S. Popov, O. I. Bliznyuk, A. M. Sarana, A. V. Shchegolev, S. G. Shcherbak   +7 more
openaire   +1 more source

Pharmacotherapy of giant cell arteritis and polymyalgia rheumatica: Prospects for the use of monoclonal antibodies to interleukin 6

Научно-практическая ревматология
Giant cell arteritis (GCA) and polymyalgia rheumatica (RPM) are immune-mediated rheumatic disease (IMRDs), which typically develop in people over 50 years of age.
Evgeny L. Nasonov, Azamat M. Satybaldyev, Elvira N. Otteva, Tatiana V. Beketova, Andrey A. Baranov   +4 more
doaj   +1 more source

Targeting interleukin-6 for noninfectious uveitis

Clinical Ophthalmology, 2015
Phoebe Lin Casey Eye Institute, Oregon Health and Science University, Portland, OR, USA Abstract: Interleukin-6 (IL-6) is a pleiotropic cytokine implicated in the pathogenesis of many immune-mediated disorders including several types of non-infectious ...
Lin P
doaj